Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) shares were down 3.9% on Wednesday . The stock traded as low as $11.80 and last traded at $11.98. Approximately 264,272 shares were traded during trading, a decline of 40% from the average daily volume of 438,172 shares. The stock had previously closed at $12.47.
Maze Therapeutics Price Performance
About Maze Therapeutics
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
- Five stocks we like better than Maze Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Dividend Capture Strategy: What You Need to Know
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Ride Out The Recession With These Dividend Kings
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
